Session: 902. Health Services and Quality Improvement: Lymphoid Malignancies: Poster III
Hematology Disease Topics & Pathways:
Research, Clinical trials, Epidemiology, Lymphomas, Non-Hodgkin lymphoma, Clinical Research, Health outcomes research, B Cell lymphoma, Health disparities research, Diversity, Equity, and Inclusion (DEI), Diseases, Aggressive lymphoma, Lymphoid Malignancies
Methods: We identified all U.S.-based clinical trials with the keyword “lymphoma” with start dates between 1/1/2014-4/1/2025 using the publicly available National Institute of Health Clinic Trial Database (https://www.clinicaltrials.gov/). We extracted data including clinical trial number, study title, study status, conditions treated, sponsor, collaborators, phase, enrollment number, funder type (i.e., NIH, Industry, or other), start date, time frame (pre-2018 versus post-2018), and CAR-T related study (i.e., yes or no). Each study was individually reviewed and all studies which enrolled adult patients with B-cell NHL subtypes were included in this analysis. We characterized all excluded studies (i.e. pediatric, transplant, solid tumor, non-NHL lymphoma, etc.). Studies that did not specifically delineate whether PLWH were excluded were labeled as being inclusive. Univariate and multivariate analyses were conducted using R software. Purposeful selection of univariate variables with P<0.20 were included in a multivariate regression model.
Results: 1,346 clinical trials were captured during the initial search, of which 58% (n=784) met criteria for inclusion in this analysis. PLWH were potentially eligible to participate in 48% of included studies (n=373). Common reasons for exclusion included leukemia-related (n=219, 36%), transplant-related (n=148, 26%), T-cell lymphoma (n=81, 14%), and pediatric-related trials (n=26, 5%). Most studies were actively recruiting (n=377, 48%) or completed (n=180, 23%) and strictly funded by industry (n=369, 47%). Few studies were solely funded by the NIH (n=69, 9%). Studies were most commonly in phase 1 (n=303, 39%) or phase 2 (n=245, 31%) and included aggressive subtypes of non-Hodgkin’s lymphoma (n=637, 81%). 380 studies were conducted after 2018; of these 56% (n=211) were inclusive of PLWH in comparison to only 40% (n=162) of studies pre-2018. Study size (p=0.017), start date (p<0.001), funding source (p<0.05), and CAR-T trials (p=0.17) met criteria for inclusion in multivariate analysis. After multivariate adjustment, studies initiated post-2018 (p<0.001), those funded by NIH (p<0.001) and other funding sources (p<0.001) were more likely inclusive of PLWH. In addition, CAR-T trials were more common post-2018 (p<0.001).
Conclusion: Nearly half of all U.S. based B-cell NHL clinical trials now include PLWH. The establishment of the ASCO-HIV Working Group in 2017 and subsequent NCCN guidelines may have contributed to this significant increase, along with advocacy from key stakeholders such as the NCI. Although there has been much research demonstrating the safety and efficacy of cytotoxic chemotherapy among PLWH, given the increased use of immunotherapy and targeted therapies, additional research demonstrating the safety profile of these agents is warranted among PLWH. PLWH have a significantly elevated risk of developing aggressive B-cell NHL; efforts to foster inclusion in clinical trials will better enable access to novel therapies, mitigate health disparities, and help reduce stigma among patients, providers, and researchers.
Disclosures: Gopal: Merck: Consultancy, Honoraria, Research Funding; I-Mab bio: Research Funding; IgM Bio: Research Funding; Takeda: Research Funding; Gilead: Consultancy, Honoraria, Research Funding; Astra Zeneca: Research Funding; Agios: Membership on an entity's Board of Directors or advisory committees; Janssen: Consultancy, Honoraria, Research Funding; BMS: Research Funding; SeaGen: Research Funding; Teva: Research Funding; Genmab: Honoraria, Research Funding; Beigene: Consultancy, Honoraria, Research Funding; Incyte: Consultancy, Honoraria; Kite: Consultancy, Honoraria; Morphosys/Incyte: Consultancy, Honoraria; ADCT: Consultancy, Honoraria; Acrotech: Consultancy, Honoraria; Merck: Consultancy, Honoraria; Karyopharm: Consultancy, Honoraria; Servier: Consultancy, Honoraria; Cellectar: Consultancy, Honoraria; Compliment: Consultancy, Current holder of stock options in a privately-held company, Honoraria; Epizyme: Consultancy, Honoraria; Lilly: Consultancy, Honoraria; Caribou: Consultancy, Honoraria; Fresenius-Kabi: Consultancy, Honoraria; Scitek: Consultancy, Honoraria; Sana: Consultancy, Honoraria.
See more of: Oral and Poster Abstracts